27.80
-1.20
(-4.14%)
As of 1:45:38 PM GMT+2. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in CNY | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 5 | 19 | 19 |
| Avg. Estimate | 5.54B | 6.34B | 25.06B | 26.78B |
| Low Estimate | 5.13B | 6.19B | 24.23B | 25.87B |
| High Estimate | 6.26B | 6.43B | 25.43B | 27.52B |
| Year Ago Sales | 5.28B | 6.15B | 23.89B | 25.06B |
| Sales Growth (year/est) | 5.01% | 3.09% | 4.89% | 6.87% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| CL4A.F | -- | -- | -- | -- |
| S&P 500 | 6.52% | 6.29% | 9.55% | 14.25% |
Upgrades & Downgrades
| Maintains | Benchmark: Buy to Buy | 11/27/2024 |
| Maintains | Benchmark: Buy to Buy | 8/22/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 5/21/2024 |
| Initiated | Macquarie: Outperform | 4/19/2024 |
| Reiterates | Benchmark: Buy to Buy | 3/22/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 3/22/2024 |